Treatment Combo Provides Consistently High PFS in CLL, SLL
First-line, fixed-duration ibrutinib plus venetoclax provides durable progression-free survival and overall survival for patients with CLL or SLL.
Jan 8, 2025
MEETING BRIEF
ASH 2024 – CLL/SLL
The latest news from ASH 2024 focused on chronic lymphocytic leukemia (CLL) including abstracts, features, and helpful conference information.
Q&A: The Vital Role of Nurses & APs in Enhancing Palliative Care for Patients With Blood Cancer Undergoing Transplant
Q&A: The Vital Role of Nurses & APs in Enhancing Palliative Care for Patients With Blood Cancer Undergoing Transplant
Physician's Weekly spoke with Richard Newcomb, MD, on the role of nurses and APs in enhancing palliative care.
Challenges in Treating Richter Transformation with Novel Agents
Challenges in Treating Richter Transformation with Novel Agents
A recent study from ASH 2024 examined the clinical features and outcomes of RT in British Columbia, comparing two eras: the chemoimmunotherapy (CIT) era (pre-2016) and the novel agents (NA) era (post-2016).
Outcomes, Distinctions in Double-Resistant/Double-Exposed CLL
Outcomes, Distinctions in Double-Resistant/Double-Exposed CLL
Treatment resistance and toxicity remain critical challenges in managing chronic lymphocytic leukemia (CLL), according to researchers at the ASH Annual Meeting.
Financial Toxicity, Adherence, and QOL in Patients With CLL on First-Line Oral Oncolytic Therapy
Financial Toxicity, Adherence, and QOL in Patients With CLL on First-Line Oral Oncolytic Therapy
Oral oncolytic therapies have revolutionized the treatment of chronic lymphocytic leukemia (CLL), offering improved outcomes and convenience for patients.
Advertisement
PW QUIZ
Advertisement
Stay connected to the latest news with Physician’s Weekly
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
